Aptevo Therapeutics Inc (APVO) - Total Assets
Based on the latest financial reports, Aptevo Therapeutics Inc (APVO) holds total assets worth $19.90 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Aptevo Therapeutics Inc cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Aptevo Therapeutics Inc - Total Assets Trend (2014–2025)
This chart illustrates how Aptevo Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Aptevo Therapeutics Inc (APVO) net assets for net asset value and shareholders' equity analysis.
Aptevo Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Aptevo Therapeutics Inc's total assets of $19.90 Million consist of 84.9% current assets and 15.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 79.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Aptevo Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Aptevo Therapeutics Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aptevo Therapeutics Inc's current assets represent 84.9% of total assets in 2025, an increase from 34.6% in 2014.
- Cash Position: Cash and equivalents constituted 79.5% of total assets in 2025, up from 3.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 62.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Aptevo Therapeutics Inc Competitors by Total Assets
Key competitors of Aptevo Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Aptevo Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.36 | 0.67 | 2.13 |
| Quick Ratio | 3.36 | 0.67 | 2.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $11.22 Million | $-1.79 Million | $34.90 Million |
Aptevo Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Aptevo Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.51 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | 74.4% |
| Total Assets | $27.19 Million |
| Market Capitalization | $5.12 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aptevo Therapeutics Inc's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Aptevo Therapeutics Inc's assets grew by 74.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Aptevo Therapeutics Inc (2014–2025)
The table below shows the annual total assets of Aptevo Therapeutics Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $27.19 Million | +74.42% |
| 2024-12-31 | $15.59 Million | -37.24% |
| 2023-12-31 | $24.84 Million | -27.39% |
| 2022-12-31 | $34.22 Million | -39.55% |
| 2021-12-31 | $56.60 Million | +5.70% |
| 2020-12-31 | $53.55 Million | +0.26% |
| 2019-12-31 | $53.41 Million | -20.87% |
| 2018-12-31 | $67.49 Million | -42.32% |
| 2017-12-31 | $117.01 Million | +27.38% |
| 2016-12-31 | $91.86 Million | -18.32% |
| 2015-12-31 | $112.46 Million | -6.26% |
| 2014-12-31 | $119.97 Million | -- |
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune … Read more